Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus TRIDESILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus TRIDESILON.
ARAZLO vs TRIDESILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Topical: Apply 0.045% gel once daily to affected areas of the face.
0.05% ointment or cream applied topically to affected area twice daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid